Despite a current lack of investment incentives; Turkey’s geographical location, market size, large and aging population, universal healthcare, potential future spending, and stage of economic development mean that it is already an immensely attractive destination for international pharma investors and will continue to be so for the foreseeable future. “Turkey…

Although the Turkish pharmaceutical market has grown significantly in recent years R&D investment remains comparatively low. However, the expertise and capabilities exist for growth in this sector. Turkish companies and international affiliates are also beginning to innovate, especially in combination products for which there is high demand. Multinational R&D investment…

pharma   The Thai pharmaceutical market is growing due to an aging, wealthier local population and a large medical tourism sector. International companies must however adapt their strategies to suit the Thai market; as must domestic concerns. With an estimated value of USD 4.5 billion, Thailand is Southeast Asia’s second largest…

Turkey In the first fifteen years of the 21st century Turkey saw rapid economic growth, greater access to healthcare, and a boom in pharmaceutical sales. The country’s healthcare sector is now entering a new era of greater govt support for the pharmaceutical industry, more focus on R&D and the potential for…

  Despite political instability, Thailand’s healthcare sector has great prospects for growth due to its expanding middle class, public health service, supply of affordable medicine, and forthcoming membership of the ASEAN Economic Community (AEC). Thailand has faced severe tests in recent years but is today emerging from them stronger. As…

Severin Schwan, CEO, Roche The FT Global Pharma and Biotechnology Conference took place in London November 16th and 17th 2015. Its theme was “bringing innovation to patients: new approaches, models, challenges”. Here is what you missed. “Declining R&D productivity, pricing, regulatory environment…” began Severin Schwan, the Austrian CEO of Roche.…

Paris, November 20th, 2015 Synerlab pursues its consolidation strategy in Europe Synerlab, a leading pharmaceutical manufacturer, announces today the acquisition of Alcala Farma, a prominent Spanish contract development and manufacturing organization (CDMO). Alcala Farma specializes in the development of proprietary formulation, which represents nearly 40% of its total €M 25…

Through greater government support for R&D, tax breaks for both foreign investors and domestic researchers and the creation of knowledge clusters, Thailand hopes to reposition itself as a regional R&D leader and pull itself out of the middle income trap. For a long time Thailand’s economy has been seen as…

Pharma Multinationals have struggled to adapt their Romanian strategies, but the local production sector appears to be flourishing. Much of this impetus relates directly to EU accession and the harmonization of manufacturing standards. “Initially, it was difficult to enact the transition, because the authorities handed us strict deadlines to make ourselves…

Romania No one can accuse the Romanian government of being lethargic when it comes to healthcare reform. After an unprecedented seven years of zero new molecules being admitted to the state reimbursement list, the pharma industry has suddenly been subjected to a whirlwind of radical refashioning and legislatory upheaval. “The industry…

Romania Once touted by the IMS as one of the “fast followers” among the world’s “pharmerging” nations and feted by the international investor community in the wake of EU accession, Romania’s pharmaceutical industry appears resurgent once more after a number of years on the back burner. In 2014, Romania’s market size…

Algeria Arnaud de Rincquesen – Managing Partner, Deloitte: Companies are willing to come to Algeria. It’s an interesting market. What matters once again is to have a job market. The biggest issue for a company settling in Algeria is to find peo- ple with specialized skills and a good academic level.…